Genomic studies of cancer are also important for developing new personalized therapies in pediatric cancer; an example of this is that the use targeted drugs for ALK alterations has shown excellent results in the treatment of anaplastic large cell lymphoma (ALCL) and childhood inflammatory myofibroblastic tumors [133]. Here, ALK is linked to anaplastic large cell lymphoma.